Abstract

BackgroundPharmacovigilance and safety reporting, which involve processes for monitoring the use of medicines in clinical trials, play a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events.ObjectiveThis study aims to demonstrate the feasibility of automating the coding of adverse events described in the narrative section of the serious adverse event report forms to enable statistical analysis of the aforementioned patterns.MethodsWe used the Unified Medical Language System (UMLS) as the coding scheme, which integrates 217 source vocabularies, thus enabling coding against other relevant terminologies such as the International Classification of Diseases–10th Revision, Medical Dictionary for Regulatory Activities, and Systematized Nomenclature of Medicine). We used MetaMap, a highly configurable dictionary lookup software, to identify the mentions of the UMLS concepts. We trained a binary classifier using Bidirectional Encoder Representations from Transformers (BERT), a transformer-based language model that captures contextual relationships, to differentiate between mentions of the UMLS concepts that represented adverse events and those that did not.ResultsThe model achieved a high F1 score of 0.8080, despite the class imbalance. This is 10.15 percent points lower than human-like performance but also 17.45 percent points higher than that of the baseline approach.ConclusionsThese results confirmed that automated coding of adverse events described in the narrative section of serious adverse event reports is feasible. Once coded, adverse events can be statistically analyzed so that any correlations with the trialed medicines can be estimated in a timely fashion.

Highlights

  • Modern health care is associated with increased costs and broad-reaching variations in care and outcomes across the global population

  • These results confirmed that automated coding of adverse events described in the narrative section of serious adverse event reports is feasible

  • Our review of text mining applications related to the identification of adverse events revealed that this source of data was underrepresented. This study addresses this gap by using serious adverse event (SAE) report forms collected during clinical trials as the primary source of data

Read more

Summary

Introduction

Background Modern health care is associated with increased costs and broad-reaching variations in care and outcomes across the global population. Pharmacovigilance and safety reporting are among the most important aspects of the conduct of clinical trials This is relevant to all clinical trials in which the benefit https://medinform.jmir.org/2021/12/e28632 XSLFO RenderX. Pharmacovigilance and safety reporting provide the basis for ensuring clinical trial participant safety and good research practice It involves processes for monitoring the use of medicines or interventions in clinical trials. It has a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events. Pharmacovigilance and safety reporting, which involve processes for monitoring the use of medicines in clinical trials, play a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call